Insulin Lispro
Metabolic / DiabetesAlso known as: Humalog, Admelog, Lyumjev
Mechanism
The first engineered insulin analog, designed to work faster than regular insulin. A simple swap of two amino acids (lysine and proline at positions B28-B29) prevents insulin molecules from clumping together, so they absorb into the bloodstream much faster after injection. Starts working in about 15 minutes and peaks at 1-2 hours — matching mealtime glucose spikes better than regular insulin.
Technical detail
Rapid-acting recombinant insulin analog produced in E. coli. Structural modification: inversion of Pro-B28 and Lys-B29 to Lys-B28/Pro-B29. This swap disrupts the hydrophobic contacts (B28 Pro–B23 Gly) critical for insulin self-association into dimers and hexamers. Result: rapid dissociation from hexameric depot at SC injection site → faster monomer availability → accelerated absorption. PK profile: onset 15 min, peak 30-90 min, duration 3-5 hours (vs. regular insulin onset 30-60 min, peak 2-4 hours). Lyumjev formulation adds treprostinil (prostacyclin analog) and citrate to further accelerate local vasodilation and absorption (onset ~5 min faster). Binds insulin receptor with identical affinity to native insulin. IGF-1R cross-reactivity comparable to human insulin. First FDA-approved insulin analog (1996, Eli Lilly).
Effects
ENDOCRINE/METABOLIC SYSTEM: Insulin lispro is a rapid-acting insulin analog created by swapping the positions of proline (B28) and lysine (B29) on the B-chain of human insulin. This single transposition prevents the self-association of insulin into hexamers at the injection site, allowing faster dissociation into active monomers [pharmacological — Eli Lilly, 1996]. Onset of action: 15-30 minutes (vs. 30-60 min for regular human insulin). Peak effect: 30-90 minutes (vs. 2-3 hours for regular). Duration: 3-5 hours (vs. 5-8 hours for regular) [RCT]. This PK profile better matches postprandial glucose excursions from meals. Lyumjev (insulin lispro-aabc) adds treprostinil (prostacyclin analog) and citrate as absorption-accelerating excipients — treprostinil causes local vasodilation at the injection site, increasing capillary blood flow and speeding insulin absorption by an additional 5-7 minutes vs. standard Humalog [RCT — Presto trial]. GLYCEMIC CONTROL: Reduces postprandial glucose excursions more effectively than regular human insulin — earlier peak means better matching to carbohydrate absorption kinetics [RCT]. HbA1c reduction comparable to regular insulin in long-term studies, but with fewer hypoglycemic events due to shorter duration (less insulin 'stacking') [RCT]. In insulin pump (CSII) use, lispro shows advantages in reducing post-meal spikes and is the standard rapid-acting analog for pump therapy [RCT]. CARDIOVASCULAR: No direct cardiovascular effects beyond glycemic control. Long-term cardiovascular outcomes equivalent to other insulin analogs [registry data]. HYPOGLYCEMIA: Reduced risk of late postprandial and nocturnal hypoglycemia compared to regular human insulin due to shorter tail of action [RCT, meta-analysis]. Severe hypoglycemia rates comparable across rapid-acting analogs (lispro, aspart, glulisine) [meta-analysis]. HISTORICAL SIGNIFICANCE: First commercially available engineered insulin analog (FDA approved 1996), proving that rational protein engineering could improve insulin pharmacokinetics. Paved the way for aspart (B28 Asp), glulisine (B3 Lys, B29 Glu), and all subsequent analog development.
Practitioner Guide
ADMINISTRATION: Subcutaneous injection or continuous subcutaneous insulin infusion (CSII pump). Standard Humalog: inject within 15 minutes before a meal (can inject at meal start). Lyumjev: inject at the start of a meal or up to 20 minutes after starting (the faster onset allows post-meal dosing flexibility, useful for patients who forget pre-meal injection or for unpredictable eating). Injection sites: abdomen (fastest absorption), upper arm, thigh. Rotate sites within the same region for consistency. DOSING: Highly individualized based on carbohydrate counting and insulin sensitivity. Typical insulin-to-carb ratio: 1 unit per 10-15g carbohydrate (varies widely). Correction factor: 1 unit drops blood glucose by 30-50 mg/dL (varies widely). Total daily mealtime insulin typically 40-60% of total daily dose (remainder is basal). INSULIN PUMP CONSIDERATIONS: Lispro is one of the standard rapid-acting insulins for pump use. In pumps, use only the insulin-specific reservoir and infusion sets. Change infusion site every 2-3 days to prevent lipodystrophy and absorption issues. Lyumjev in pumps: approved for pump use, may offer improved postprandial control, but some users report increased infusion site irritation due to the treprostinil/citrate excipients. HUMALOG VS LYUMJEV: For patients with adequate control on Humalog, switching to Lyumjev provides marginal improvement (~5-7 min faster onset). The benefit is most apparent in patients struggling with postprandial spikes despite optimal pre-meal timing. Lyumjev may cause transient injection site pain/irritation in ~3% of patients (vs. <1% for Humalog) due to the citrate buffer. STACKING RISK: Even with lispro's shorter duration vs. regular insulin, insulin stacking (giving correction doses too frequently) remains a risk. Wait at least 2-3 hours between correction doses. Use insulin-on-board calculations (built into most modern pumps and CGMs). STORAGE: Unopened vials/pens: refrigerate (2-8°C). In-use vials: room temperature for up to 28 days. In-use KwikPens: room temperature for up to 28 days. Do not freeze. Protect from heat and light. BIOSIMILAR LANDSCAPE: Insulin lispro biosimilars (Admelog/insulin lispro-aadm, Insulin Lispro Sanofi) are available at lower cost — clinically equivalent to Humalog. Encourage use for cost-sensitive patients. COST: Without insurance, Humalog remains expensive ($150-300/vial). Biosimilars and authorized generics (Lilly's Insulin Lispro) available at significant discounts. Lilly caps out-of-pocket cost at $35/month for insured patients.
Research Summary
TIER 1: Pivotal RCTs (Anderson et al., 1997 — NEJM): insulin lispro vs. regular human insulin in Type 1 diabetes, demonstrated improved postprandial glucose control and reduced hypoglycemia. Multiple Phase III RCTs in Type 1 and Type 2 diabetes confirming non-inferiority or superiority in postprandial control. Lyumjev PRONTO trials (Presto, Pronto-T1D, Pronto-T2D): faster onset and improved 1-hour postprandial glucose vs. Humalog, with comparable HbA1c and safety. FDA approved: Humalog 1996, Lyumjev 2020. Meta-analyses confirming rapid-acting analogs reduce hypoglycemia vs. regular insulin. TIER 2: Systematic reviews of rapid-acting insulin analogs (Cochrane — Siebenhofer et al., 2006; updated reviews). Pump therapy comparisons across rapid-acting analogs. Cost-effectiveness analyses showing modest clinical advantage for significant cost increase over regular insulin (debated in health economics literature). Biosimilar interchangeability studies. TIER 3: Real-world registry data from diabetes registries (T1D Exchange, Swedish NDR) confirming outcomes consistent with RCTs. Practitioner experience reports on Lyumjev injection site pain. Pump user community feedback on analog performance in hybrid closed-loop systems. KEY FINDINGS: Insulin lispro is a foundational therapy in modern diabetes management with an excellent safety and efficacy track record spanning 30 years. Its main advantage over regular human insulin is better postprandial glucose control with less hypoglycemia. Lyumjev represents an incremental improvement in speed. The clinical differences between rapid-acting analogs (lispro, aspart, glulisine) are minimal — selection is often driven by device preferences and cost. GAPS: No large cardiovascular outcome trials specific to lispro (insulin in general has neutral CV outcomes). Lyumjev long-term pump compatibility data still accumulating. Ultra-rapid formulations for closed-loop artificial pancreas systems actively being studied. ACTIVE TRIALS: Lyumjev in hybrid closed-loop systems (Medtronic 780G, Omnipod 5). Head-to-head Lyumjev vs. Fiasp (faster aspart). Concentrated insulin lispro (U-200) in insulin-resistant populations.